BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu G, Zhou W, Li X, Guo L, He T, Zhao J, Gong L. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. Front Immunol 2021;12:712351. [PMID: 34504494 DOI: 10.3389/fimmu.2021.712351] [Reference Citation Analysis]
2 Schonfeld M, Zhao J, Komatz A, Weinman SA, Tikhanovich I. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma. J Biol Chem 2020;295:7126-37. [PMID: 32245889 DOI: 10.1074/jbc.RA120.013401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wang R, Guo H, Tang X, Zhang T, Liu Y, Zhang C, Yu H, Li Y. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells. Inflammation 2021. [PMID: 34536158 DOI: 10.1007/s10753-021-01547-3] [Reference Citation Analysis]
4 Wang HY, Wang YP, Zeng X, Zheng Y, Guo QH, Ji R, Zhou YN. Circular RNA is a popular molecule in tumors of the digestive system (Review). Int J Oncol 2020;57:21-42. [PMID: 32377736 DOI: 10.3892/ijo.2020.5054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Xiong C, Wang Z, Wang G, Zhang C, Jin S, Jiang G, Bai D. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma. Invest New Drugs 2021. [PMID: 33942202 DOI: 10.1007/s10637-021-01126-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology 2021:S0016-5085(21)03652-0. [PMID: 34678217 DOI: 10.1053/j.gastro.2021.10.015] [Reference Citation Analysis]
9 Shi X, Li Q, Wang Y. Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e23957. [PMID: 33545975 DOI: 10.1097/MD.0000000000023957] [Reference Citation Analysis]
10 Liang J, Zhi Y, Deng W, Zhou W, Li X, Cai Z, Zhu Z, Zeng J, Wu W, Dong Y, Huang J, Zhang Y, Xu S, Feng Y, Ding F, Zhang J. Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma. PeerJ 2021;9:e11627. [PMID: 34178478 DOI: 10.7717/peerj.11627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Wu Y, Zhang J, Li Q. Autophagy, an accomplice or antagonist of drug resistance in HCC? Cell Death Dis 2021;12:266. [PMID: 33712559 DOI: 10.1038/s41419-021-03553-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bai M, Chen J, Xu W, Dong S, Liu Q, Lin B, Huang X, Yao G, Song S. Elephantopinolide A-P, germacrane-type sesquiterpene lactones from Elephantopus scaber induce apoptosis, autophagy and G2/M phase arrest in hepatocellular carcinoma cells. European Journal of Medicinal Chemistry 2020;198:112362. [DOI: 10.1016/j.ejmech.2020.112362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Lv W, Yao Q, Wang F. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients. Disease Markers 2022;2022:1-27. [DOI: 10.1155/2022/9428660] [Reference Citation Analysis]
14 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
15 Bévant K, Coulouarn C. A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies. EBioMedicine 2020;54:102737. [PMID: 32268278 DOI: 10.1016/j.ebiom.2020.102737] [Reference Citation Analysis]
16 Wang L, Ge X, Zhang Z, Ye Y, Zhou Z, Li M, Yan H, Wu L, Bai Q, Li J, Zhu J, Wang Y. Identification of a Ferroptosis-Related Long Noncoding RNA Prognostic Signature and Its Predictive Ability to Immunotherapy in Hepatocellular Carcinoma. Front Genet 2021;12:682082. [PMID: 34745200 DOI: 10.3389/fgene.2021.682082] [Reference Citation Analysis]
17 Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Reference Citation Analysis]
18 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hu B, Yang XB, Sang XT. Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:315-30. [PMID: 33204664 DOI: 10.2147/JHC.S272109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Cai Y, Wu D, Zhan L. CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis. Clin Res Hepatol Gastroenterol 2021;:101796. [PMID: 34500119 DOI: 10.1016/j.clinre.2021.101796] [Reference Citation Analysis]
21 Wang H, Jiang W, Wang H, Wei Z, Li H, Yan H, Han P. Identification of Mutation Landscape and Immune Cell Component for Liver Hepatocellular Carcinoma Highlights Potential Therapeutic Targets and Prognostic Markers. Front Genet 2021;12:737965. [PMID: 34603396 DOI: 10.3389/fgene.2021.737965] [Reference Citation Analysis]
22 Zhong X, Liao H, Hu S, Luo K, Zhu H. The diterpenoid adenanthin upregulates the expression of natural killer group 2D receptor ligands in hepatocellular carcinoma cells. Mol Cell Probes 2021;59:101759. [PMID: 34265372 DOI: 10.1016/j.mcp.2021.101759] [Reference Citation Analysis]
23 Du X, Zhang Y. Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma. Front Genet 2020;11:614888. [PMID: 33391356 DOI: 10.3389/fgene.2020.614888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
24 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
25 Meng T, Tong Z, Yang MY, Zhang Y, Liu Y, Wang ZZ, Zhu LX, Wu J. Immune implication of FAM83D gene in hepatocellular carcinoma. Bioengineered 2021;12:3578-92. [PMID: 34308751 DOI: 10.1080/21655979.2021.1950260] [Reference Citation Analysis]
26 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
27 Rao Q, Li M, Xu W, Pang K, Guo X, Wang D, Liu J, Guo W, Zhang Z. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020;14:765-75. [DOI: 10.1007/s12072-020-10064-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
28 Yu Z, Song Y, Cai M, Jiang B, Zhang Z, Wang L, Jiang Y, Zou L, Liu X, Yu N, Mao X, Peng C, Liu S. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:21294-308. [PMID: 34470916 DOI: 10.18632/aging.203459] [Reference Citation Analysis]
29 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
30 Sun L, Lin Y, Wang G, Zhang L, Hu L, Lu Z. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer. Biosci Rep 2021;41:BSR20203115. [PMID: 33439969 DOI: 10.1042/BSR20203115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Hui Y, Leng J, Jin D, Liu D, Wang G, Wang Q, Wang Y. A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma. Dis Markers 2021;2021:1986159. [PMID: 34721731 DOI: 10.1155/2021/1986159] [Reference Citation Analysis]
32 Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
33 Miao L, Zhang Z, Ren Z, Li Y. Application of Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:699060. [PMID: 34513678 DOI: 10.3389/fonc.2021.699060] [Reference Citation Analysis]
34 Xu L, Jian X, Liu Z, Zhao J, Zhang S, Lin Y, Xie L. Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma. Front Genet 2021;12:741226. [PMID: 34646307 DOI: 10.3389/fgene.2021.741226] [Reference Citation Analysis]
35 Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 2021;6:128. [PMID: 33776057 DOI: 10.1038/s41392-021-00507-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
36 Han JW, Yoon SK. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics 2021;13:1387. [PMID: 34575463 DOI: 10.3390/pharmaceutics13091387] [Reference Citation Analysis]
37 Xu H, Liang XL, Liu XG, Chen NP. The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1132-40. [PMID: 34295562 DOI: 10.21037/jgo-21-251] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Xiong Q, Bai Y, Shi R, Wang J, Xu W, Zhang M, Song T. Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition. Bioact Mater 2021;6:3744-55. [PMID: 33898875 DOI: 10.1016/j.bioactmat.2021.03.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Reference Citation Analysis]
40 Deng M, Fang L, Li SH, Zhao RC, Mei J, Zou JW, Wei W, Guo RP. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Mutagenesis 2021;36:369-79. [PMID: 34467992 DOI: 10.1093/mutage/geab032] [Reference Citation Analysis]
41 Yan Q, Zheng W, Wang B, Ye B, Luo H, Yang X, Zhang P, Wang X. A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Min 2021;14:29. [PMID: 33962640 DOI: 10.1186/s13040-021-00261-y] [Reference Citation Analysis]
42 Shang BB, Chen J, Wang ZG, Liu H. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. PeerJ 2021;9:e12315. [PMID: 34754620 DOI: 10.7717/peerj.12315] [Reference Citation Analysis]
43 Ni W, Bian S, Zhu M, Song Q, Zhang J, Xiao M, Zheng W. Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma. Front Oncol 2021;11:629327. [PMID: 33718205 DOI: 10.3389/fonc.2021.629327] [Reference Citation Analysis]
44 Shen Y, Yang F, Peng H, Zhang G, Zhu F, Xu H, Shi L. Anti-tumor effect of Yanggan Huayu granule by inducing AKT-mediated apoptosis in hepatocellular carcinoma. J Ethnopharmacol 2022;282:114601. [PMID: 34487847 DOI: 10.1016/j.jep.2021.114601] [Reference Citation Analysis]
45 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Song X, Wang TX, Zhu XN, Tan SK. Immunological and prognostic significance of CBX2 expression in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2021; 29(19): 1118-1129 [DOI: 10.11569/wcjd.v29.i19.1118] [Reference Citation Analysis]
47 Guo L, Li H, Fan T, Ma Y, Wang L. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. Life Sci 2021;279:119359. [PMID: 33753114 DOI: 10.1016/j.lfs.2021.119359] [Reference Citation Analysis]
48 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zhang H, Zhang Y, Dong J, Zuo S, Meng G, Wu J, Wei J. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. Cell Oncol (Dordr) 2021. [PMID: 34491549 DOI: 10.1007/s13402-021-00633-w] [Reference Citation Analysis]
50 Long H, Zhuang B, Huang G, Li X, Lin M, Long J, Xie X, Liu B. Safety and Local Efficacy of Laser Ablation for the Extrahepatic Metastasis of Hepatocellular Carcinoma: An Available Treatment Strategy. Coatings 2020;10:951. [DOI: 10.3390/coatings10100951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Chen H, Li Y, Xiao SY, Guo J. Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma. BMC Cancer 2021;21:278. [PMID: 33726698 DOI: 10.1186/s12885-021-08012-2] [Reference Citation Analysis]